skip to Main Content

November 5, 2013

Codexis Appoints Greg Hughes, Ph.D., as Vice President, Strategic Alliance & Product Development

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Nov. 5, 2013–
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for
pharmaceutical, biofuel and chemical production, today announced the
appointment of Greg Hughes, Ph.D., as Vice President, Strategic Alliance
& Product Development, effective October 28, 2013. Dr. Hughes spent the
last 11 years in Process Chemistry at Merck with a primary focus in
developing and implementing biocatalysis technology.

“We are very pleased to have Greg join the Codexis team as we continue
to position our biocatalyst business for market leadership and growth,”
said John Nicols, President and CEO of Codexis. “Greg was a driving
force behind our landmark partnership with Merck for the development and
deployment of a biocatalytic production process for Merck’s type 2
diabetes drug Januvia® (sitagliptin). He knows firsthand the value
creation that Codexis’ biocatalysis technology can bring to our
pharmaceutical customers. Greg can help us break down potential internal
resistance to adoption of new technologies at large companies. In his
role at Codexis, Greg will be working to build deeper alliances with
major pharmaceutical companies, while also helping to develop new
products to broaden the commercial applicability of our biocatalyst
platform.”

“Codexis has quickly become the market leader in biocatalysis for the
pharmaceutical industry, and I am very pleased to be joining the Company
at this time with so many near-term growth opportunities,” said Dr.
Hughes. “Our customized enzymes can benefit customers in both the
pharmaceutical industry and other complex chemistry markets, and I look
forward to building off of my previous experience working with Codexis
to help grow both our customer and product pipelines in the months
ahead.”

Prior to joining Codexis, Dr. Hughes worked at Merck beginning in 2002
in a variety of roles, most recently as Executive Director, Enabling
Technologies in the Process Chemistry department. His responsibilities
at Merck were focused on process chemistry and in particular on the
application of biocatalysis technology within Merck’s research and
development and manufacturing groups.

Dr. Hughes holds a Ph.D. in Organic Chemistry from the University of
Toronto
and a B.S. in Chemistry from the University of New Brunswick. He
completed his postdoctoral work at the Massachusetts Institute of
Technology
.

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and
implementation of biocatalytic solutions to meet customer needs for
rapid, cost-effective and sustainable process development – from
research to manufacturing. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the
expansion of Codexis’ pharmaceutical business, Codexis’ abilities to
capitalize on business opportunities in the pharmaceutical and other
markets and the benefits that Codexis’ enzymes can provide its
customers. You should not place undue reliance on these forward-looking
statements because they involve known and unknown risks, uncertainties
and other factors that are, in some cases, beyond Codexis’ control and
that could materially affect actual results. Factors that could
materially affect actual results include Codexis’ dependence on a
limited number of customers and a limited number of products in its
pharmaceutical business, Codexis’ abilities to develop and commercialize
new products for the pharmaceutical market, Codexis’ dependence on its
collaborators and the successful management of these relationships in
developing and commercializing new products, Codexis’ ability to deploy
its technology into market spaces adjacent to its pharmaceutical
business and Codexis’ customers receiving regulatory and market approval
of their pharmaceutical products. Additional factors that could
materially affect actual results can be found in Codexis’ Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission on
August 9, 2013, including under the caption “Risk Factors.” Codexis
expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.

Source: Codexis, Inc.

Codexis, Inc.
Investors
Paul Cox, 212-362-1200
ir@codexis.com
or
Media
Jemma
Connor, +44 161 359 3255
jemma.connor@notchcommunications.co.uk

Back To Top
Close search
Search